Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded by Hilary Schultz, Persephoni BioPartners is a biotechnology venture studio located in the United States. The firm specializes in partnering with innovators at the earliest stages to develop therapeutics from scientific breakthroughs. They focus on building high-impact biotech companies and currently manage a portfolio of four companies.
Persephoni BioPartners invests in early-stage biotech companies that aim to improve human health through therapeutic, diagnostic, or platform-based innovations. They target ventures in autoimmunity, oncology, and viral diseases, seeking foundational science supported by strong preclinical data and a clear path to clinical relevance. Investment stages include pre-seed, seed, and seed+ (extension) rounds.
Notable portfolio companies include LampRNA Therapeutics, which develops a lysosome-mediated RNA degrader platform; Telos Therapeutics, focused on exosome-based therapies for autoimmunity and oncology; InnoVira, working on an EBV-specific antiviral medication; and Monarch Therapeutics, offering modular adaptors for personalized therapy programs.
Submit your pitch through their website form at [URL]. Ensure your proposal highlights foundational science and preclinical data relevant to human health innovations.
Persephoni BioPartners runs a venture studio program that partners with early-stage biotech innovators to develop therapeutics from scientific breakthroughs. Interested founders can apply through their website.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.